RegeneRx's T?4 Promotes Recovery of Peripheral Neuropathy in Type II Diabetic Mice
ROCKVILLE, Md.--(BUSINESS WIRE)--Aug 29, 2012 - RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) reports that U.S. researchers have found that Thymosin Beta 4 (TÎ²4) promotes statistically significant recovery of peripheral neuropathy in type II diabetic mice including recovery of neurovascular dysfunction in the sciatic nerve and recovery of neurological function. Peripheral neuropathy is one of the most common complications of diabetes mellitus and affects 60%-70% of patients with diabetes.
According to the research team, “These data indicate that Tβ4 likely acts on endothelial cells and Schwann cells to preserve and/or restore vascular function in the sciatic nerve which facilitates improvement of peripheral nerve function under diabetic neuropathy. Thus, Tβ4 has potential for the treatment of diabetic peripheral neuropathy.”
The study was conducted by researchers at The Henry Ford Hospital in Detroit, MI and Oakland University in Rochester, MI, and published by Wang, L., et al., Thymosin 4 promotes the recovery of peripheral neuropathy in type II diabetic mice, Neurobiol. Dis. (2012), http://dx.doi.org/10.1016/j.nbd.2012.08.002.
About RegeneRx Biopharmaceuticals, Inc. (www.regenerx.com)
RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, two strategic licensing agreements in China and the EU, and has an extensive worldwide patent portfolio covering its products.
Forward Looking Statements
Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Please view these and other risks described in the Company's filings with the Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” section of the annual report on Form 10-K for the year ended December 31, 2011, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.
Contact: For RegeneRx:
Lori Smith, 301-208-9191
Posted: August 2012